WO2018115341A1 - D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz - Google Patents
D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz Download PDFInfo
- Publication number
- WO2018115341A1 WO2018115341A1 PCT/EP2017/084199 EP2017084199W WO2018115341A1 WO 2018115341 A1 WO2018115341 A1 WO 2018115341A1 EP 2017084199 W EP2017084199 W EP 2017084199W WO 2018115341 A1 WO2018115341 A1 WO 2018115341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivatives
- identity
- homologs
- group
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 83
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 65
- 208000002193 Pain Diseases 0.000 title claims abstract description 26
- 208000000094 Chronic Pain Diseases 0.000 title claims abstract description 11
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 11
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 9
- 230000001684 chronic effect Effects 0.000 title abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 11
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 11
- 230000001537 neural effect Effects 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 13
- 125000006850 spacer group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 229940035676 analgesics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000009460 calcium influx Effects 0.000 claims description 3
- 239000002858 neurotransmitter agent Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 31
- 108091006146 Channels Proteins 0.000 description 29
- 150000002500 ions Chemical class 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 15
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 13
- 238000005259 measurement Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 229960002811 ziconotide Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 230000010412 perfusion Effects 0.000 description 8
- 101150104494 CAV1 gene Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 238000012402 patch clamp technique Methods 0.000 description 4
- 229920001184 polypeptide Chemical group 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091058550 ω-conotoxin Proteins 0.000 description 4
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010040923 D3 peptide Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229940125400 channel inhibitor Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- 229940020463 prialt Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- QUOGESRFPZDMMT-RXMQYKEDSA-N (2r)-2-amino-6-(diaminomethylideneamino)hexanoic acid Chemical compound OC(=O)[C@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-RXMQYKEDSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- ICASMSGEUGPHGI-UHFFFAOYSA-N 3-amino-1h-pyrazole-5-carboxylic acid Chemical compound NC=1C=C(C(O)=O)NN=1 ICASMSGEUGPHGI-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102100031366 Ankyrin-1 Human genes 0.000 description 1
- 102100036818 Ankyrin-2 Human genes 0.000 description 1
- 102100036817 Ankyrin-3 Human genes 0.000 description 1
- 101100029765 Arabidopsis thaliana PIA2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 241001638933 Cochlicella barbara Species 0.000 description 1
- 241000237971 Conus magus Species 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000796140 Homo sapiens Ankyrin-1 Proteins 0.000 description 1
- 101000928344 Homo sapiens Ankyrin-2 Proteins 0.000 description 1
- 101000928342 Homo sapiens Ankyrin-3 Proteins 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108700012358 P/Q-type calcium channel Proteins 0.000 description 1
- 102000050761 P/Q-type calcium channel Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 201000000464 cone-rod dystrophy 2 Diseases 0.000 description 1
- 108050003126 conotoxin Proteins 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- BPKIMPVREBSLAJ-UHFFFAOYSA-N prialt Chemical compound N1C(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(CO)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(N)CSSC2)CSSCC(C(NC(CCCNC(N)=N)C(=O)NC(CO)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CSSC3)C(N)=O)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(C(C)O)NC(=O)C2NC(=O)C3NC(=O)C(CC(O)=O)NC(=O)C1CC1=CC=C(O)C=C1 BPKIMPVREBSLAJ-UHFFFAOYSA-N 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HKYHBMLIEAMWRO-UHFFFAOYSA-N sy002454 Chemical compound OC(=O)C1=CC([N+]([O-])=O)=NN1 HKYHBMLIEAMWRO-UHFFFAOYSA-N 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 108091058538 ω-conotoxin MVIIA Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Definitions
- the present invention relates to a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2-D3 homologs having at least 50% identity and derivatives of RD2 and D3 for use as analgesics, for use in analgesic therapy, for use in the treatment of chronic and / or neuropathic pain, and / or for inhibiting N-type neuronal calcium channels (NCC).
- the invention further relates to a method for reducing the release of neurotransmitters compared to a control and to a method for inhibiting an N-type NCC using the composition as defined above.
- Figures from the Deutscheratetician show that more than 12 million people in Germany are affected by long-lasting, chronic pain and / or neuropathic pain. Neuropathic pain develops after damage or disease of afferent systems in the peripheral or central nervous system.
- Drug therapy is possible with a 50-80% pain reduction, one
- antidepressants tri- / tetracyclic antidepressants, selective serotonin / norepinephrine reuptake inhibitors
- long-acting opioids eg carbamazepine
- anticonvulsants with effect on neuronal sodium channels eg carbamazepine
- topical therapeutics lidocaine patches, capsaicin high-dose patches
- pharmacological therapies that have an effect on neuronal calcium channels, such as gabapentin, pregabalin and ziconotide (Prialt®).
- gabapentin and pregabalin-specific P / Q-type calcium channel inhibitors and ziconotide are the only approved specific N-type calcium channel inhibitor.
- Ziconotide is a cyclic peptide of 25 amino acids and was originally derived from the venom of the
- Ziconotide is used in people who suffer from extreme pain and for whom all other treatment options are unsuccessful. Prialt® approval is based on the results of three Phase III clinical trials involving more than 1,200 patients. In all studies, ziconotide was able to reduce pain well compared to placebo, including severe treatment-resistant chronic pain as a result of Cancer or AIDS. Among other things, the additional amount of opioids required was reduced by the additional intrathecal use of ziconotide. Ziconotide causes less adverse effects compared to morphine.
- ziconotide causes severe central nervous effects such as dizziness, nausea, nystagmus, confusion, gait, memory, blurred vision, headache, asthenia, vomiting and somnolence in 88% of patients.
- Ziconotide is used for pain therapy as it is the only approved specific N-type
- Calcium channel inhibitor which, even with very severe pain, e.g. caused by
- compositions are to be provided which have fewer side effects and accordingly inhibit N-type NCC specifically and selectively and have no influence on the function of L-type NCC.
- the compositions to be provided should be administrable in a simple manner, preferably by oral administration.
- inhibition of N-type NCC channels should be reversible to avoid permanent pain insensitivity and damage.
- Concentration changes of a drug have great effects. This can easily lead to under- or overdoses, which may each be dependent on the specific metabolism and can lead to unwanted side effects or long-term damage.
- Another object was to provide a composition containing active ingredients that ensure passage of the blood-brain barrier.
- Another object was to provide stable, by the way of the enteral, intravenous, subcutaneous, intraperitoneal, intrarhinal and / or oral application of compositions that unfold their effect at the target site, the N-type NCC.
- This object is achieved in one embodiment by a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2, D3, homologs with at least 50% identity and derivatives of RD2 and D3 for use as analgesics.
- Another object of the present invention is a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologues having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2, D3, homologues with at least 50% identity and derivatives of RD2 and D3 for use in pain therapy.
- the invention further provides a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2, D3, homologues having at least 50 % identity and derivatives of RD2 and D3 for use in the treatment of chronic and / or neuropathic pain.
- Another object of the invention is a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologues having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2, D3, homologues with at least 50% identity and derivatives of RD2 and D3 for inhibiting N-type neuronal calcium channels (NCC).
- NCC N-type neuronal calcium channels
- the peptide consists essentially of D-amino acids.
- the term "essentially of D-amino acids” means that the peptides to be used according to the invention are at least 50%, 60%, preferably 75%, 80, 81, 82, 83, 84%, particularly preferably 85, 86, 87, 88, 89%, 90, 91, 92, 93, 94, 95%, in particular 96%, 97%, 98%, 99%, 100% contain or consist of D-amino acids.
- D-peptides in vivo are much more resistant to proteases, offering the potential for oral administration with long elimination half-lives. Furthermore, they are usually not or only slightly immunogenic.
- Another embodiment relates to the composition described above for use in an application of 1 microgram to 1 gram per kilo of body weight, preferably 100 micrograms to 10 mg / kg of body weight, more preferably from 0.5 to 5 mg / kg of body weight.
- One embodiment relates to the above-described composition for enteral,
- the composition described above exhibits an IC 50 value of 1 nanomolar to 1 millimolar for N-type NCC, preferably from 10 nM to 100 ⁇ , particularly preferably from 100 nM to 10 ⁇ , in particular from 100 nM to 1 ⁇ .
- composition to be used according to the invention contains in a variant or consists of peptides selected from the group consisting of or comprising
- ANK2 (free N-terminus, preferably amidated C-terminus): rkrirl06yhinr (SEQ ID NO: 9);
- ANK3 (free N-terminus, preferably amidated C-terminus): rkrirl06yhwnr (SEQ ID NO: 10);
- ANK4 (free N-terminus, preferably amidated C-terminus): rkrirlvyhwnr (SEQ ID NO: 11);
- ANK6 (free N-terminus, preferably amidated C-terminus): rkrirlvtkkkr (SEQ ID NO: 13);
- ANK7 (free N-terminus, preferably amidated C-terminus): rkrvr102thikr (SEQ ID NO: 14);
- ANK15 (free N-terminus, preferably amidated C-terminus): rprvrl06yhwnr (SEQ ID NO: 15);
- ANK16 (free N-terminus, preferably amidated C-terminus): rkr07rlvtkrnr (SEQ ID NO: 16);
- ANK18 (free N-terminus, preferably amidated C-terminus): rpr07rlhtkkkr (SEQ ID NO: 18); with 02: 4-fluoro-phenylalanine (D) 06: phenylglycine (D) 07: D-homoarginine.
- the derivatives of the peptides to be used according to the invention and described above are cyclized or amidated peptides.
- the peptides to be used according to the invention are covalently linked to the free N-terminus at the free C-terminus and are then cyclized accordingly. Also by the ring closure is advantageously effected that the carboxyl group is no longer present at the free C-terminus.
- the peptides advantageously have an amino acid sequence in which the cyclization of the linear molecule z. B. by a covalent bond of the first with the last amino acid, z. B. over a Condensation reaction, is done.
- z. B. by other amino acids are linked together.
- the linkage of the second amino acid with the last amino acid may be mentioned.
- ptihthnrrrrr (SEQ ID NO: 1) represents tlhthnrrrrrp with the cyclized peptides of the sequence Ihthnrrrrrpt, hthnrrrrrptl, thnrrrrrptlh, hnrrrrrptlht, nrrrrrptlhth, rrrrrptlhthn, rrrptlhthnr, rrptlhthnrr, rrptlhthnrr, rptlhthnrrr, rptlhthnrrr, rptlhthnrrr, rptlhthnrrr, rptlhthnrrrr and the label "CRD2
- the production of cyclized peptides is state of the art, and can be carried out, for example, by the
- cyclization across the first and last amino acid of the peptide causes no "open" ends of the peptide chain to exist which are often targets for peptide degrading activities in cells, animals or humans, for example, by aminopeptidases and carboxypeptidases.
- the peptides to be used according to the invention are amidated in a further embodiment of the invention at the free C-terminus, and therefore an acid amide group is present instead of the carboxyl group.
- an acid amide group is present instead of the carboxyl group.
- carboxyl group (-COOH group) is thus a
- the peptide is therefore particularly advantageously amidated at the free C-terminus.
- the further object is achieved with particular advantage that a peptide without negative charge excess is present, which can bind affine to the target molecule and is obtainable in a simple manner.
- the peptides to be used according to the invention are each extended by one or two amino acids at the N-terminus and / or C-terminus or shortened compared to the original sequence.
- One alternative has one terminus of one or two additional amino acids, while the other term has one or two
- the peptides are preferably extended from the original sequence at the C-terminus by an amino acid selected from the group of the amino acids rlht, preferably r.
- Preferred derivatives are cyclized (cyclic) peptides, amidated peptides and / or peptide sequence extended by one amino acid, preferably Aginin r at the C-terminus, in particular D3r rprtrlhthrnrr (SEQ ID NO: 5), and cyclized D3r.
- Further preferred derivatives are cyclized RD2 and the respective linear amidated forms and / or peptide sequence RD2r ptlhthnrrrrrrrr (SEQ ID NO: 19) extended by one amino acid, preferably Aginin r at the C terminus.
- the subject of the present invention is therefore also the peptide RD2r ptlhthnrrrrrrr (SEQ ID NO: 19); a 13-mer based on RD2 which is extended at the C-terminus by one amino acid, preferably r.
- the subject of the invention is also the amidated and / or cyclized form cRD2r (analogous to cRD2).
- Another object is the peptide RD2r as well as the amidated and / or cyclized form, preferably cRD2r for use in medicine, or as a medicament, preferably for use in the treatment of
- peptides to be used according to the invention are:
- identity in the present description, the terms "homologous" or
- Nucleic acid sequence / polypeptide sequence defined over the respective entire sequence length, as determined by comparison with the aid of the program GAP based on the algorithm of
- Needleman, S.B. and Wunsch, C.D. (J. Mol. Biol. 48: 443-153) is calculated by setting the following parameters for amino acids: gap creation penalty: 8 and gap extension penalty: 2; and the following parameters for nucleic acid gap creation penalty: 50 and gap extension penalty: 3.
- Two amino acid sequences are identical for the purposes of the present invention if they have the same amino acid sequence.
- the homology or identity is determined by the respective total length of the corresponding peptides.
- the comparison, and thus the determination of the identity or homology takes place only over subareas.
- polypeptides to be used according to the invention have a homology of at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78 , 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%.
- composition contains or consists of
- the polymer to be used according to the invention contains 2, 3, 4, 5, 6, 7, 8, 9, 10 or more of the monomer peptides described above.
- dimers selected from the group consisting of or containing RD2D3, D3RD2, D3D3 and RD2RD2 or homologs or derivatives thereof.
- Polymers can be prepared, for example, via chemical synthesis or peptide synthesis.
- the peptides can be linearly linked to one another, in particular as described above.
- the peptides are branched together to form the polymer according to the invention.
- a branched polymer may according to the invention be a dendrimer in which the monomers are covalently or non-covalently linked to one another.
- the peptides may also be linked to a platform molecule (such as PEG or sugar) to form a branched polymer.
- the monomer peptides are coupled head to head, tail to tail, or head to tail, with or without additional linkers, and in one alternative by total covalent linkage, with or without additional linkers (eg, one or more amino acids), the two remaining ends cycled.
- the peptides to be used according to the invention are covalently linked to further amino acids, linkers, spacers and / or functional groups.
- these other amino acids, linkers, spacers and / or functional groups do not alter the properties of the peptide.
- the further amino acids, linkers, spacers and / or functional groups cause a change in the properties of the peptide.
- the selectivity and / or affinity of the polymers of the invention with respect to the N-type NCC is enhanced.
- a linker is to be understood as meaning one or more molecules that are covalent
- Binders are bound to the peptides, which linkers may also be linked to each other by covalent bonds.
- functional groups molecules which are covalently bound to the peptides.
- the functional groups contain biotin groups. This allows strong covalent attachment to streptavidin.
- the peptides contain so-called spacers.
- a spacer is understood to mean a molecule which is bound to the peptide via covalent bonds and possesses certain physical and / or chemical properties by which the properties of the peptide are changed.
- hydrophilic or hydrophobic, preferably hydrophilic, spacers are used.
- Hydrophilic spacers are selected from the group of molecules formed from polyethylene glycol, sugar, glycerol, poly-L-lysine or beta-alanine. The peptides are linked in one alternative with another substance.
- these substances are drugs or active ingredients, defined in accordance with the Medicinal Products Act ⁇ 2 respectively. ⁇ 4 (19), as of September 2012.
- active substances are therapeutically active substances which are used as medicinally active substances.
- the substances are carriers for the controlled reaction
- Drug release also called drug carrier systems
- drug carrier systems drugs that transport the active substances specifically to the vicinity of specific organs or cells and release them in a controlled manner.
- the substances are substances that enhance the action of the peptides.
- such compounds are aminopyrazole and / or aminopyrazole derivatives.
- Aminopyrazole derivatives according to the invention is 3-aminopyrazole-5-carboxylic acid or 3-nitropyrazole-5-carboxylic acid and all derivatives in which the heterocyclic CH group has been replaced by -CR- or -N- or -O- or -S- , as well as any derived peptidic dimers, trimers or tetramers
- Aminopyrazole trimer Another alternative is compounds which improve the solubility of the peptides and / or the passage of the blood-brain barrier.
- the substance is linked to the peptide, where the linkage is a covalent bond or the linkage is not a covalent bond.
- the link is over here
- Hydrogen bridge hydrophilic, hydrophobic, electrostatic interaction or binding and / or steric immobilization.
- Another object of the present invention is a method for reducing the release of neurotransmitters compared to a control characterized in that a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologues having at least 50% identity and derivatives of RD2 or D3 and polymers containing or consisting of RD2, D3,
- Homologs with at least 50% identity and derivatives of RD2 and under D3 for use as analgesics with the N-type NCC is brought into contact.
- the calcium influx through an NCC is reduced as compared to a control by the method of the invention.
- the subject of the invention is also a method for inhibiting an N-type NCC in comparison to a control characterized in that it comprises a composition consisting of or containing peptides selected from the group consisting of or containing RD2, D3, homologs with at least 50% Identity and derivatives of RD2 or D3 and polymers containing RD2, D3, homologues with at least 50% identity and
- contacting means that there are conditions which allow interaction between the peptides to be used according to the invention and the N-type NCC, in particular physical and / or chemical interactions, such as the formation of coordinative bonds or hydrogen bonds.
- Selecting a control is a routine part of an experimental approach.
- an organism is used which is identical to the organism to be examined in an alternative.
- the organism to be examined is treated as in the composition according to the invention or brought into contact in the broadest sense, while the control is not subjected to this method.
- organism also includes parts of organisms, tissues, tissue samples, individual cells or cell cultures, parts of cells such as membrane-containing NCC channels, preferably of the N-type or L-type, or artificial membranes such.
- B double lipid membrane containing neuronal calcium channels, preferably of the N-type and / or L-type. Both the control and the organism to be examined are selected from the list above.
- the control is defined according to the specifications of the clinical trials.
- inhibition means the reduction of the activity of neuronal calcium channels, preferably of the N-type, with respect to a control by the composition to be used according to the invention.
- the control according to the invention is not brought into contact with this composition.
- the control may be contacted with known inhibitors.
- inhibition is determined at a concentration equal to or equal to the IC50 value.
- compositions to be used according to the invention inhibit N-type NCC at least 10%, 15%, 20%, 25%, preferably 30%, particularly preferably 40%, 50%, 60%, 70%, 80%, in particular 90% or 100%.
- the inhibition according to the invention by means of the so-called patch Clamp technique determined.
- the ion current through the calcium channel is measured at different voltages.
- the inhibition of the neuronal calcium channel is thus determined by the reduction of the ion current.
- a reduction of the ionic current by at least 10%, 15%, 20%, 25%, preferably 30%, 35%, more preferably 40, 42, 44, 46, 48, 50%, 52, 54, 56, 58, 60%, 70%, 80%, especially 90% or 100%.
- the reduction is determined at a concentration of peptides equal to the IC 50 value.
- the patch clamp measurement is determined by contacting the corresponding channel with a composition of concentration 150 nM to be used according to the invention.
- the methods according to the invention are characterized in that the function of L-type NCC is not changed with respect to a control. In other words, the calcium influx through the L-type NCC is not changed from a control.
- the peptides to be used according to the invention act specifically and / or selectively on N-type NCC.
- the present invention also provides the use of the peptides to be used according to the invention as a replacement for conotoxin.
- contacting the NCC or membrane containing NCC or the corresponding sources containing NCC can be performed in vitro (ex vivo).
- the invention also relates to the treatment of chronic and / or neuropathic pain, ie a treatment for pain relief, in which the individual to be treated by enteral, intravenous, subcutaneous, intraperitoneal, intrarhinal or oral administration, preferably oral administration, the peptides according to the invention to be used in a Concentration of 1 micrograms to 1 g / kg body weight.
- the invention also relates to a process in which the peptides to be used according to the invention are incorporated into pharmaceutical formulations by means of customary processes known to the person skilled in the art.
- the invention also relates to the use of the above-described peptides in pharmaceutical formulations.
- a pharmaceutical formulation comprising the peptides to be used according to the invention and described above is therefore likewise an object of the present invention.
- the present invention further relates to the use of a composition of claim 1 for the preparation of a painkiller, a medicament for use in pain therapy and / or a medicament for the treatment of chronic and neuropathic pain.
- Another object of the invention is the use of a composition according to claim 1 for inhibiting N-type neuronal calcium channels NCC.
- the coding regions of the two different alpha-pore-forming units (CaValphal) of the voltage-gated calcium channel were fused in frame (C-terminal fusion) to the fluorescent proteins as follows: the rabbit CaV1.2 unit
- CaVbeta2e (UniProtKB: Q8VGC3-2) was coupled to mRFP (CaVbeta2e-mRFP) and CaVbeta4 (UniProtKB: O00305.2) to mCherry (CaVbeta4-mCherry).
- tsA201 cells were transiently transfected with either CaV1.2-YFP and CaVbeta2e-mRFP or CaV2.2-GFP and CaVbeta4-mCherry. Transfection was by Lipofectamine 2000TM (Invitrogen) and the successfully transfected cells were identified by fluorescence signal. Electrophysiological recordings were made 24-48 hours after transfection.
- Ion currents were measured by Whole Cell Patch-Clamp technique with an EPC-10 amplifier with implemented PatchMaster software (HEKA, Electronics). Barium was used as a carrier. Borosilicate glass pipettes with resistances of 0.9-2 ⁇ were connected to a Sutter P 1000 puller (Harvard Apparatus) used and heat-smoothed by means of Narishige MF-830 microforge superficially on the top.
- the external measurement solution was 140 mM TEA-MeSO.sub.3, 10 mM BaCl.sub.2, 10 mM HEPES (pH 7.3) and, as the inner measurement solution, 135 mM Cs-MeSO.sub.3, 10 mM EGTA, 5 mM CsCl.sub.2, 1 mM MgCl.sub.2, 4 mM MgATP, 0.4 mM Na2GTP and 10 mM HEPES (pH 7.3).
- the data analysis was done using a
- RD2 In order to investigate the pharmacological effect of RD2, cells were detached and transferred to a perfusion flow which either contained the test substance or not. The observations were performed under constant perfusion to ensure a constant concentration of the test substance.
- RD2 was in DMSO with a
- CaV2.2 is located in the pre-synaptic nerve terminals and mediate the
- CaV1 .2 the L-type calcium channel is predominantly expressed in the heart and responsible for coupling the electrical activation of cardiomyocytes with myofilament contraction.
- the ion currents were recorded by CaV1.2 and CaVbeta2e co-expressing cells and remained nearly unchanged after exposure to 150 nM RD2 (Figure 2A: Representative uptake of current mediated by a CaV1.2 channel elicited during a 40 ms pulse , starting from a holding potential of -90 mV to + 10 mV before and after contact with a composition containing 150mM RD2
- Fig. 2B no change in current on perfusion with 150 nM RD2).
- RD2 was tested at a concentration of 150 nM for its ability to block ion currents mediated via the CaV2.2 and CaV1.2 channels. Assays were performed in CaV2.2 and CaV1 .2 channel expressing tsA201 cells using the whole-cell patch clamp technique. RD2 blocks the CaV2.2 channel while the CaV1.2 channel is insensitive to RD2 at the concentration tested ( Figure 3).
- the coding region of the human alpha pore-forming units (CaValphal) of the voltage-gated calcium channel CaV2.2 (UniProtKB: Q00975-1) was fused with GFP to CaV2.2-GFP.
- the beta subunit CaVbeta4 (UniProtKB: O00305.2) was fused to mCherry to form CaVbeta4 mCherry.
- tsA201 cells were transiently co-transfected with CaV2.2-GFP and CaVbeta4-mCherry. Transfection was by Lipofectamine 2000TM (Invitrogen) and the successfully transfected cells were identified by fluorescence signal. Electrophysiological recordings were made 24-48 hours after transfection.
- Ion currents were measured by Whole Cell Patch-Clamp technique with an EPC-10 amplifier with implemented PatchMaster software (HEKA, Electronics). Barium was used as a carrier. Borosilicate glass pipettes with resistors of 0.9-2 ⁇ were attached to a Sutter P-1000 puller (Harvard Apparatus) and heat-finished with Narishige MF-830 microforge superficially on the tip.
- the external measurement solution was 140 mM TEA-MeSO.sub.3, 10 mM BaCl.sub.2, 10 mM HEPES (pH 7.3) and, as internal measurement solution, 135 mM Cs-MeSO.sub.3, 10 mM EGTA, 5 mM CsCl.sub.2, 1 mM MgCl.sub.2, 4 mM MgATP, 0.4 mM Na.sub.2 GTP and 10 mM HEPES (pH 7.3).
- the data analysis was done using a
- D3 was in DMSO with a
- FIG. 4A, B Representative recording of the current intensity mediated by a CaV 2.2- Channel, generated during a pulse of 40 ms, starting from a holding potential of -90 mV to + 20 mV before and after in contact bring with a composition containing 150mM D3 .; 4B: D3-induced inhibition is reversible after reperfusion with an external Ringer's solution. The current was recorded during successive pulses of -90 mV + 20 mV, every 5 sec.).
- Representative ion current leads mediated by the CaV2.2 channel were triggered during a 40 ms pulse from -90 mV to +20 mV before and after exposure to 150 nM cD3r (7A left panel).
- 8A Representative ion current leads mediated by the CaV2.2 channel were triggered during a 40 ms pulse from -90 mV to +20 mV before and after exposure to 150 nM cRD2r (8A left panel).
- the right figure 8A shows the time course of blockage in a representative cell during successive pulses from -90 mV to +20 m every five seconds.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780080349.2A CN110167578A (zh) | 2016-12-23 | 2017-12-21 | 用于治疗慢性和神经性疼痛的d-对映体肽 |
MX2019007217A MX2019007217A (es) | 2016-12-23 | 2017-12-21 | Peptidos d-enantiomericos para la terapia del dolor cronico y neuropatico. |
EP17826511.2A EP3558336A1 (de) | 2016-12-23 | 2017-12-21 | D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz |
US16/470,616 US11224632B2 (en) | 2016-12-23 | 2017-12-21 | Methods of treating chronic and neuropathic pain mediated by N-type neuronal calcium channels using D-enantiomeric peptides |
RU2019118602A RU2759722C2 (ru) | 2016-12-23 | 2017-12-21 | D-энантиомерные пептиды для терапии хронической и невропатической боли |
JP2019534338A JP7143304B2 (ja) | 2016-12-23 | 2017-12-21 | 慢性疼痛および神経障害性疼痛を治療するためのd-エナンチオマーペプチド |
BR112019012936A BR112019012936A2 (pt) | 2016-12-23 | 2017-12-21 | peptídeos d-enanioméricos para a terapia de dor crônica e neuropática |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016125645.5 | 2016-12-23 | ||
DE102016125645.5A DE102016125645A1 (de) | 2016-12-23 | 2016-12-23 | D-enantiomere Peptide zur Therapie von chronischem und neuropathischem Schmerz |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018115341A1 true WO2018115341A1 (de) | 2018-06-28 |
Family
ID=60953845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/084199 WO2018115341A1 (de) | 2016-12-23 | 2017-12-21 | D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz |
Country Status (9)
Country | Link |
---|---|
US (1) | US11224632B2 (de) |
EP (1) | EP3558336A1 (de) |
JP (1) | JP7143304B2 (de) |
CN (1) | CN110167578A (de) |
BR (1) | BR112019012936A2 (de) |
DE (1) | DE102016125645A1 (de) |
MX (1) | MX2019007217A (de) |
RU (1) | RU2759722C2 (de) |
WO (1) | WO2018115341A1 (de) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005049537A1 (de) | 2005-10-17 | 2007-04-26 | Forschungszentrum Karlsruhe Gmbh | Zyklische Peptide und Verfahren zu deren Herstellung |
WO2015043567A1 (de) * | 2013-09-26 | 2015-04-02 | Forschungszentrum Jülich GmbH | Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz |
DE102015003676A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH Fachbereich Patente | Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0004056D0 (sv) * | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
WO2011032233A1 (en) * | 2009-09-21 | 2011-03-24 | The University Of Queensland | Novel omega conotoxin peptides |
RU2508295C2 (ru) | 2012-03-22 | 2014-02-27 | Общество с ограниченной ответственностью "Биофармокс" | Синтетические пептиды с ненаркотическим типом анальгетического действия |
DE102012108598A1 (de) * | 2012-09-14 | 2014-04-10 | Forschungszentrum Jülich GmbH | Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung |
DE102012102998B4 (de) * | 2012-04-05 | 2013-12-05 | Forschungszentrum Jülich GmbH | Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung |
JP6434903B2 (ja) * | 2012-04-05 | 2018-12-05 | フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングForschungszentrum Juelich GmbH | 多価アミロイドβに結合するD−ペプチド含有ポリマー及びその使用 |
DE102013016002A1 (de) * | 2013-09-26 | 2015-03-26 | Forschungszentrum Jülich GmbH | Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung |
EP2991664B1 (de) | 2013-04-30 | 2019-09-04 | Forschungszentrum Jülich GmbH | Agenzien zur prävention und therapie von folgeerkrankungen von hiv und anderer viraler infektionen |
DE102015003503A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH | Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz |
-
2016
- 2016-12-23 DE DE102016125645.5A patent/DE102016125645A1/de active Pending
-
2017
- 2017-12-21 CN CN201780080349.2A patent/CN110167578A/zh active Pending
- 2017-12-21 MX MX2019007217A patent/MX2019007217A/es unknown
- 2017-12-21 WO PCT/EP2017/084199 patent/WO2018115341A1/de active Application Filing
- 2017-12-21 RU RU2019118602A patent/RU2759722C2/ru active
- 2017-12-21 EP EP17826511.2A patent/EP3558336A1/de active Pending
- 2017-12-21 JP JP2019534338A patent/JP7143304B2/ja active Active
- 2017-12-21 US US16/470,616 patent/US11224632B2/en active Active
- 2017-12-21 BR BR112019012936A patent/BR112019012936A2/pt not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005049537A1 (de) | 2005-10-17 | 2007-04-26 | Forschungszentrum Karlsruhe Gmbh | Zyklische Peptide und Verfahren zu deren Herstellung |
WO2015043567A1 (de) * | 2013-09-26 | 2015-04-02 | Forschungszentrum Jülich GmbH | Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz |
DE102015003676A1 (de) * | 2015-03-20 | 2016-09-22 | Forschungszentrum Jülich GmbH Fachbereich Patente | Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz |
Non-Patent Citations (3)
Title |
---|
JOSEPH G. MCGIVERN: "Targeting N-type and T-type calcium channels for the treatment of pain", DRUG DISCOVERY TODAY, vol. 11, no. 5-6, 1 March 2006 (2006-03-01), AMSTERDAM, NL, pages 245 - 253, XP055463667, ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03662-7 * |
NEEDLEMAN, S. B.; WUNSCH, C. D., J. MOL. BIOL., vol. 48, pages 443 - 453 |
SMITH, T. F.; WATERMAN, M. S, ADV. APPL. MATH., vol. 2, 1981, pages 482 - 489 |
Also Published As
Publication number | Publication date |
---|---|
RU2759722C2 (ru) | 2021-11-17 |
DE102016125645A1 (de) | 2018-06-28 |
JP7143304B2 (ja) | 2022-09-28 |
US20190314447A1 (en) | 2019-10-17 |
US11224632B2 (en) | 2022-01-18 |
MX2019007217A (es) | 2019-09-11 |
BR112019012936A2 (pt) | 2019-12-10 |
CN110167578A (zh) | 2019-08-23 |
EP3558336A1 (de) | 2019-10-30 |
RU2019118602A3 (de) | 2021-01-29 |
RU2019118602A (ru) | 2021-01-25 |
JP2020502243A (ja) | 2020-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69637021T2 (de) | Zusammensetzungen zur Erzielung von Analgesie und zur Hemmung der Progression neuropathischer Schmerzerkrankungen | |
DE69911400T2 (de) | Zusammensetzungen enhaltende 5-hydroxyindol als Modulator eines nikotinischen Rezeptors | |
EP3132043B1 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
DE69737065T2 (de) | Insulin c-peptide | |
EP1805215A2 (de) | Chemisch modifizierte iapp-peptidanaloga | |
EP3346273A1 (de) | Neue, von d3 agbeleitete d-enantiomere peptide und deren verwendung | |
EP2991664B1 (de) | Agenzien zur prävention und therapie von folgeerkrankungen von hiv und anderer viraler infektionen | |
EP3747454B1 (de) | Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz | |
EP1056467B1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
AT506150A1 (de) | Zyklisches und cystein-freies peptid | |
EP3558336A1 (de) | D-enantiomere peptide zur therapie von chronischem und neuropathetischem schmerz | |
EP2227246A1 (de) | Behandlung von fibrosen und lebererkrankungen | |
DE102010013887A1 (de) | Fusionsprotein und dessen Verwendungen | |
EP3271374B1 (de) | Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz | |
DE102021005922A1 (de) | Inhibierung der Interaktion zwischen viralen Spike Proteinen von SARS-CoV-2 und dem humanen Angiotensin-konvertierenden Enzym 2 (hACE2) | |
DE10035854A1 (de) | Schlangentoxin und dessen Verwendung als Arzneimittel | |
DE60031132T2 (de) | Zusammensetzungen zur eröffnung der wasserkanäle und medizinische zusammensetzungen zur opthalmischer verwendung | |
WO2004096368A1 (de) | Bekämpfung von hi-virus infektionen mit oxidierten blutproteinen | |
DE102014003262A1 (de) | Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz | |
DE102018110542A1 (de) | D-Peptid-basiertes Prodrug (RD2-Folsäure) für die Therapie von Alzheimer | |
DE10027777A1 (de) | Transfektionsverfahren | |
DE10240894A1 (de) | Verstärkung der Resorption von Subtanzen über die Haut und Schleimhaut | |
DE102012108599A1 (de) | A-Beta-Oligomer-bindende Peptide und deren Verwendung | |
WO2008131746A2 (de) | Mittel zur präventiven antiinfektiven behandlung eines patienten | |
DE102013007405A1 (de) | Agenzien zur Prävention und Therapie von HIV und anderer viraler Infektionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17826511 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019534338 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019012936 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2019118602 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2017826511 Country of ref document: EP Effective date: 20190723 |
|
ENP | Entry into the national phase |
Ref document number: 112019012936 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190621 |